Q2 EPS Estimates for Haemonetics Lowered by Zacks Research

Key Points

• Zacks Research has revised Haemonetics Corporation's Q2 2026 EPS estimate from $1.16 to $1.12, indicating potential concerns over the company's earnings performance.
• Haemonetics reported $1.10 EPS for its last quarter, surpassing the consensus estimate but showing a revenue decline of 4.4% year-over-year.
• Multiple ratings have shifted for Haemonetics, with firms like Raymond James lowering their price target from $105.00 to $78.00 while maintaining an "outperform" rating.

Haemonetics Corporation (NYSE:HAE - Free Report) - Zacks Research lowered their Q2 2026 EPS estimates for Haemonetics in a note issued to investors on Monday, August 25th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.12 for the quarter, down from their prior forecast of $1.16. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q3 2026 earnings at $1.28 EPS, Q4 2026 earnings at $1.30 EPS, FY2026 earnings at $4.80 EPS, Q1 2027 earnings at $1.20 EPS, Q2 2027 earnings at $1.28 EPS, Q3 2027 earnings at $1.37 EPS, Q4 2027 earnings at $1.39 EPS, FY2027 earnings at $5.24 EPS and Q1 2028 earnings at $1.44 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business's quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

HAE has been the topic of a number of other reports. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Raymond James Financial lowered Haemonetics from a "strong-buy" rating to an "outperform" rating and lowered their price objective for the company from $105.00 to $78.00 in a research note on Monday, August 11th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Mizuho cut their target price on Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, Barrington Research decreased their price target on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $85.18.

Haemonetics Stock Performance

Shares of HAE stock opened at $55.10 on Thursday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The company's fifty day moving average price is $68.64 and its two-hundred day moving average price is $66.13. The firm has a market capitalization of $2.65 billion, a P/E ratio of 16.85, a P/E/G ratio of 1.02 and a beta of 0.40. Haemonetics has a 12 month low of $50.68 and a 12 month high of $94.99.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently made changes to their positions in HAE. Stifel Financial Corp raised its position in shares of Haemonetics by 7.3% during the 4th quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier's stock valued at $1,154,000 after acquiring an additional 1,006 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Haemonetics by 16.0% during the first quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier's stock valued at $3,543,000 after purchasing an additional 7,678 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Haemonetics by 434.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock worth $24,522,000 after purchasing an additional 255,338 shares during the period. GAMMA Investing LLC raised its holdings in shares of Haemonetics by 11,225.0% during the first quarter. GAMMA Investing LLC now owns 17,667 shares of the medical instruments supplier's stock worth $11,230,000 after purchasing an additional 17,511 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Haemonetics by 7.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,396 shares of the medical instruments supplier's stock worth $851,000 after buying an additional 936 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.